Plaz4 1000 System
Infected wounds, including those with multidrug-resistant bacteria (e.g., MRSA) and chronic (non-healing) wounds
Pre-clinicalActive
Key Facts
Indication
Infected wounds, including those with multidrug-resistant bacteria (e.g., MRSA) and chronic (non-healing) wounds
Phase
Pre-clinical
Status
Active
Company
About Plasmology4
Plasmology4 is developing a novel medical device platform based on non-thermal plasma (Plaz4 Technology) for therapeutic applications, initially targeting infected and chronic wounds. Its lead product, the Plaz4 1000 system, has received FDA Breakthrough Device designation and is aiming for regulatory approval in 2027. The company boasts a strong IP position with 48 issued patents and is led by a management team with deep experience in medical devices and biomedical research. Plasmology4 represents a potential paradigm shift in treating antimicrobial-resistant infections without drugs.
View full company profile